Cebix's Series B - II Round

Cebix raised a round of funding on November 13, 2014.

Cebix is developing Ersatta, a disease-modifying replacement peptide for the treatment of complications associated with diabetes. Ersatta is a long-acting form of C-peptide that, unlike other products…

Articles about Cebix's Series B - II Round: